Printer Friendly

VTI APPOINTS DR. PREM SARIN VICE PRESIDENT OF RESEARCH AND ANNOUNCES PRELIMINARY DATA FROM HGP-30 SCID MOUSE STUDY

 BETHESDA, Md., May 3 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) and Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) announced the appointment of Prem Sarin, Ph.D., as vice president of research for Viral Technologies, Inc. (VTI), a joint venture of CEL-SCI Corporation and Alpha 1 Biomedicals, Inc.
 Sarin served as deputy chief, Laboratory of Tumor Cell Biology, at the National Cancer Institute, Bethesda, under Dr. Robert Gallo from 1975 to 1991. In this capacity, he was actively engaged in research on AIDS drugs and AIDS vaccines as well as working on different approaches to the treatment of AIDS. Sarin is the holder of several national and international honors and awards.
 Maximilian de Clara, chairman of Viral Technologies, Inc., said: "We are very pleased to have Dr. Prem Sarin join VTI and make his vast expertise in the AIDS field available to us. Dr. Sarin has been a consultant to VTI since 1991, and we expect him to contribute greatly to our HGP-30 AIDS vaccine program in the future."
 At a recent Washington meeting titled "Vaccines: New Technology and Applications," Sarin presented the preliminary results from an SCID mouse experiment conducted at the Johns Hopkins University, Baltimore. SCID mice are unable to produce mature T-cells or B-cells which are required for a normal immune response, and these mice are useful for evaluating potential AIDS vaccines and therapeutics. Since they have no effective immune system, human white blood cells containing T-cells and B-cells can be transplanted into SCID mice. Human T-cells can be infected by the AIDS virus, but mouse T-cells cannot be infected by HIV. The preliminary experiments that Sarin presented suggest that white blood cells from an HGP-30 vaccinated volunteer prevented HIV infection in 75 percent of the SCID mice tested when challenged with live HIV virus, in comparison to 25 percent of the controls. VTI plans additional experiments in the SCID mouse model.
 HGP-30 differs from other AIDS vaccine candidates in that it is a synthetic copy of an immunodominant portion of the p17 "core" protein of the AIDS virus. It was chosen as a vaccine candidate because it has the potential, as shown in VTI's ongoing human trials, to elicit both cell- mediated as well as humoral immune responses against the HIV virus.
 HGP-30 has already been tested in two clinical trials in healthy, HIV-negative individuals at the Kobler AIDS Center, London (United Kingdom) and at the LAC-USC Medical Center and the San Francisco General Hospital. The results of both clinical trials indicated HGP-30 to be well tolerated.
 The patent rights to HGP-30 are owned by Viral Technologies, Inc. (VTI), a joint venture of CEL-SCI Corporation and Alpha 1 Biomedicals, Inc.
 -0- 5/3/93
 /CONTACT: Geert Kersten of CEL-SCI Corporation, 703-549-5293, or Vincent F. Simmon, Ph.D., of Alpha 1 Biomedicals, Inc., 301-564-4400/
 (CELI ALBM)


CO: CEL-SCI Corporation; Alpha 1 Biomedicals; Viral Technologies, Inc. ST: Maryland IN: MTC SU: PER

MH-DC -- DC009 -- 3600 05/03/93 09:06 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:490
Previous Article:HILTON CALLS FOR END TO 'FREQUENT TRAVEL HYPE'; URGES GUESTS TO COMPARE THE REWARDS
Next Article:GLENDALE FEDERAL BANK SEEKS OTS DEPOSITIONS IN SUPERVISORY GOODWILL CASE AGAINST GOVERNMENT


Related Articles
UPDATE ON HGP-30 AIDS VACCINE PRESENTED AT BERLIN AIDS CONFERENCE
NEW HUMAN STUDIES BEGIN WITH AIDS VACCINE CANDIDATE HGP-30
HUMAN HIV STUDY WITH HGP-30 SHOWS SIGNIFICANTLY INCREASED LEVEL OF PROTECTION IN SCID MOUSE TEST
CEL-SCI'S HGP-30 AIDS VACCINE SHOWS SIGNIFICANT PROTECTION AGAINST HIV CHALLENGE
CEL-SCI ANNOUNCES PRESENTATION OF CLINICAL DETAILS OF AIDS STUDY WITH HGP-30 VACCINE AT XI INTERNATIONAL CONFERENCE ON AIDS
HGP-30 AIDS Vaccine Shows Recognition of Major HIV Subtypes in Human and Animal Studies
CEL-SCI Corporation and AIDS ReSEARCH Alliance Announce Results of HGP-30 AIDS Vaccine Study, Plan Further Study
AIDS Vaccine Effective in Animal Tests; Human HGP-30 Antibodies Shown to Recognize HIV Subtypes
AIDS Vaccine Effective in Animal Tests; Human HGP-30 Antibodies Shown to Recognize HIV Subtypes
AIDS Vaccine Effective in Animal Tests.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters